Immunostimulatory Oligonucleotides

Author(s): Pawel Bodera

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 5 , Issue 1 , 2011

Become EABM
Become Reviewer


RNA-protein interactions have been characterized often. Above all, the proteins which are associated with the studied RNA should be precisely identified. The pharmaceutical compositions containing nucleic acids and/or other compounds can be administered by any suitable route for administering medications. The immunostimulatory oligonucleotides play the role of antisense drugs which are being researched to treat cancers (including lung cancer, colorectal carcinoma, pancreatic carcinoma, malignant glioma and malignant melanoma), diabetes, Amyotrophic lateral sclerosis (ALS), and diseases such as asthma and arthritis with an inflammatory component. The immunostimulatory oligonucleotides may contain one or more natural or unnatural amino acid residues which are connected to the polymer by peptide (amide) linkages. The vaccine against cancer which has been produced during this work can be prophylactic or therapeutic. Since most studies so far have been performed with first-generation antisense oligonucleotides (ODNs), it is interesting to observe how second-generation immune stimulatory drug candidates with enhanced potency and efficacy can further improve the utility of this class of therapeutic agents. The aim of this article is to review most significant patents on immunostimulatory oligonucleotides.

Keywords: RNA, CpG sequence motifs, immunostimulatory oligonucleotides, antisense oligonucleotides (ODNs), RNP complex, ribonucleoprotein enzyme (RNP), malignant melanoma, diabetes, ALS, DNA, CpG-ODN, RNase H, sLex, TLRs, PRR, PAMPs, CD8+ T cells, CD28, CTLA-4, NSCLC, CTLs, PNA, CLL), hyperthermia, B-CLL, CD25, CD27, ADCC, CDC, CDRs, Treg

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [87 - 93]
Pages: 7
DOI: 10.2174/187221311794474856

Article Metrics

PDF: 21